Nastech Pharmaceutical Company Inc.

Nastech Pharmaceutical Company Inc.
About Nastech
Nastech Pharmaceutical Company Inc. is an emerging pharmaceutical company dedicated to the development and commercialization of unique products to treat diseases in areas where our innovations will have the greatest impact on improving human health.
Through our proprietary nasal drug delivery and tight junction biology programs, we seek to introduce innovative products and overcome drug delivery barriers that others cannot. Our science and capabilities can provide for the safe, effective, and convenient delivery of a range of compounds, including small molecules, peptides and complex proteins. Our product pipeline spans a variety of therapeutic areas ranging from obesity to breakthrough cancer pain and demonstrates our commitment to pursue products and diseases where we can offer significant contributions.
Research and Development
Nastech's research and development programs focus on three primary areas that drive the discovery and development of safe and effective pharmaceuticals. These areas include tight junction modulation science, intracellular RNAi delivery and nasal drug delivery. Each of these areas are distinct programs, but in concert provide synergies that would otherwise be unavailable.
These areas in combination with our advanced high-throughput formulation science capabilities will enable Nastech and our partners to create innovative products that treat disabling diseases and improve health.
Contact Nastech
Corporate Headquarters
3830 Monte Villa Parkway
Bothell, Washington 98021
425-908-3600
425-908-3650
Map and Directions
New York Manufacturing Facility
45 Davids Drive
Hauppauge, NY 11788
631-273-0101
631-273-0252
Map and Directions

Clinical Operations
425-908-3600
425-908-3655
clinicalops@nastech.com
Corporate Communications
and Investor Relations
425-908-3639
425-908-3650
ir@nastech.com

Human Resources
425-908-3600
425-908-3655
hr@nastech.com Marketing and Business Development
425-908-3600
425-908-3650
bd@nastech.com
Comments: 0
Votes:4